346 related articles for article (PubMed ID: 33135220)
1. Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms.
Ferrari A; Scandura J; Masciulli A; Krichevsky S; Gavazzi A; Barbui T
Eur J Haematol; 2021 Feb; 106(2):250-259. PubMed ID: 33135220
[TBL] [Abstract][Full Text] [Related]
2. Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms.
Brabrand M; Hansen KN; Laursen CB; Larsen TS; Vestergaard H; Abildgaard N
Eur J Haematol; 2019 Mar; 102(3):227-234. PubMed ID: 30450659
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients.
Venton G; Turcanu M; Colle J; Thuny F; Chebrek S; Farnault L; Mercier C; Ivanov V; Fanciullino R; Suchon P; Jarrot PA; Aissi K; Roche P; Cautela J; Arcani R; Costello R
Eur J Intern Med; 2019 Oct; 68():71-75. PubMed ID: 31421946
[TBL] [Abstract][Full Text] [Related]
4. Clinical Phenotype and Outcomes of Pulmonary Hypertension Associated with Myeloproliferative Neoplasms: A Population-based Study.
Montani D; Thoré P; Mignard X; Jaïs X; Boucly A; Jevnikar M; Seferian A; Jutant EM; Cottin V; Fadel E; Simonneau G; Savale L; Sitbon O; Humbert M
Am J Respir Crit Care Med; 2023 Sep; 208(5):600-612. PubMed ID: 37311222
[No Abstract] [Full Text] [Related]
5. Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients.
Jindamai Y; Rattarittamrong E; Phrommintikul A; Yongsmith L; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Int J Hematol; 2020 Nov; 112(5):631-639. PubMed ID: 32700192
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension.
Khan NA; Ahuja KA; Wang X; Chaisson NF
Leuk Lymphoma; 2021 Jun; 62(6):1458-1465. PubMed ID: 33494630
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients.
Lee MW; Ryu H; Choi YS; Song IC; Lee HJ; Yun HJ; Sun BJ; Jeong JO; Jo DY
Blood Res; 2020 Jun; 55(2):77-84. PubMed ID: 32429621
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
[TBL] [Abstract][Full Text] [Related]
9. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
10. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
11. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
12. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
[TBL] [Abstract][Full Text] [Related]
13. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
14. Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm.
Yaylali YT; Yilmaz S; Akgun-Cagliyan G; Kilic O; Kaya E; Senol H; Ozen F
Med Princ Pract; 2020; 29(5):486-491. PubMed ID: 32069470
[TBL] [Abstract][Full Text] [Related]
15. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
17. Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms.
Krečak I; Gverić-Krečak V; Lapić I; Rončević P; Gulin J; Fumić K; Krečak F; Holik H; Duraković N
Acta Clin Belg; 2021 Feb; 76(1):32-39. PubMed ID: 31455178
[No Abstract] [Full Text] [Related]
18. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
20. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
